phenyl acetate has been researched along with imatinib mesylate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bandyopadhyay, S; Cheng, JX; Li, J; Oh, ST; Traer, E; Tyner, JW; Zhou, A | 1 |
| Nilsson, A; Salamon, D; Stenke, L; Wallvik, J; Yektaei-Karin, E; Zovko, A | 1 |
2 other study(ies) available for phenyl acetate and imatinib mesylate
| Article | Year |
|---|---|
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Topics: Acetamides; Acetates; Animals; Apoptosis; Cell Proliferation; Cholesterol; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Esterification; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mice; Mutation; Protein Kinase Inhibitors; Sulfonamides; Sulfonic Acids; Xenograft Model Antitumor Assays | 2017 |
Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis.
Topics: Acetates; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclopropanes; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukotriene Antagonists; Protein Kinase Inhibitors; Quinolines; Receptors, Leukotriene; Signal Transduction; Sulfides | 2018 |